官网首页 › 研究观点 › 观点正文

江苏恒瑞医药二季度业绩超预期,授权合作收入成最大亮点!

发布于 2025-09-03

<blockquote style="margin: 6px 0px;padding: 6px 12px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;border-left: 4px solid rgba(0, 0, 0, 0.08);color: rgb(0, 0, 0);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-size: medium;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;"><span leaf="">创新药收入同比增长21.8%,海外授权收入持续发力,摩根士丹利维持“超配”评级,目标价85港元。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p></blockquote><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">8月20日,摩根士丹利发布江苏恒瑞医药(1276.HK)2025年二季度业绩快报分析。报告显示,公司二季度总收入达86亿元人民币,同比增长12.5%,</span><strong style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"><span leaf="">超出市场预期15%</span></strong><span leaf="">。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">若剔除与默克(MRK)合作的2亿美元首付款,药品销售收入仍达到71亿元,保持12.5%的稳定增长。这份成绩单在当前的医药市场环境下显得尤为亮眼。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><hr style="margin: 16px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;border-width: 0.5px 0px 0px;border-right-style: initial;border-bottom-style: initial;border-left-style: initial;border-right-color: initial;border-bottom-color: initial;border-left-color: initial;border-image: initial;border-top-style: solid;border-top-color: rgba(0, 0, 0, 0.08);color: rgb(0, 0, 0);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-size: medium;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;" /><h2 style="margin-top: 0px !important;margin-right: 0px;margin-bottom: 0px;margin-left: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">01 业绩亮点:利润增长超预期,授权合作成助推器</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">恒瑞医药二季度业绩最引人注目的是其利润表现。经常性净利润达到24.1亿元,同比增长17.6%;而报告净利润更是高达25.7亿元,同比增长24.6%。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><strong style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"><span leaf="">利润增长主要来自于授权合作收入</span></strong><span leaf="">。据摩根士丹利计算,若剔除与默克合作带来的税后收益,经常性利润仍达到12亿元,同比增长23%,显示公司主营业务盈利能力持续增强。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">毛利率保持在84.4%的高水平,与去年同期持平。费用方面,销售费用率同比下降0.3个百分点,管理与研发费用率则分别上升0.3和4.9个百分点。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">研发投入大幅增加,表明公司正在持续加大创新药布局。</span></p><h2 style="margin: 24px 0px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">02 业务结构:创新药占比持续提升,收入结构优化明显</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">上半年数据显示,恒瑞医药的创新药收入达到75.7亿元,</span><strong style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"><span leaf="">同比增长21.8%</span></strong><span leaf="">,已占全部药品销售收入的约55%。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">这意味着公司创新药收入已经超过传统仿制药,成为主要收入来源。相比之下,仿制药销售收入仅增长1.6%,增速明显放缓。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">这种收入结构变化符合公司向创新驱动转型的战略方向,也获得了资本市场的认可。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">创新药占比提升不仅改善了收入结构,还提高了盈利能力,为持续增长奠定基础。</span></p><h2 style="margin: 24px 0px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">03 投资者关注:七大焦点问题指向未来增长潜力</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">摩根士丹利报告列出了投资者最关注的七大问题,这些问题在很大程度上将决定恒瑞医药未来的估值走向。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">全球合作伙伴的临床开发计划和关键授权资产的催化路径,特别是NewCo Kailera旗下的GLP-1产品线,以及最近授权给GSK的PDE3/4产品。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">管理层对进一步对外授权机会和进度的评论,这也是近期业绩超预期的主要因素。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">国内创新药审批和销售前景,尤其是在当前监管环境下的表现。2025年国家医保目录和商业保险清单谈判对关键新药(如HER2 ADC)的预期。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">美国仿制药销售表现和前景,特别是首仿药Abranaxe的表现,以及应对关税不确定性的缓解措施。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">销售、管理和研发成本的未来趋势。未来6-12个月的数据读出催化剂。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><h2 style="margin: 24px 0px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">04 估值分析:摩根士丹利维持超配评级,目标价85港元</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">摩根士丹利对恒瑞医药维持“超配”评级,</span><strong style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"><span leaf="">目标价定为85港元</span></strong><span leaf="">,较当前股价有约8%的上涨空间。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">估值方法采用DCF(现金流折现)模型,假设加权平均资本成本(WACC)为8.2%,终端增长率为3.5%。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">同时采用SOTP(分类加总估值)方法进行交叉验证:仿制药业务按2025年预期市盈率10倍估值,与中国其他大型仿制药企业持平;创新药国内潜力按峰值销售额的3.0-3.5倍估值,与中国领先生物科技公司2030年的市销率区间一致。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><h2 style="margin: 24px 0px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 35px;color: rgba(0, 0, 0, 0.86);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf=""><span textstyle="" style="font-size: 18px;font-weight: bold;">05 风险因素:上行与下行风险并存</span></span></h2><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">虽然摩根士丹利总体看好恒瑞医药,但报告也提示了潜在的风险因素。</span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">上行风险包括:对外授权交易和合作收入超预期;创新药批准时间早于预期;药品销售增长快于预期。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">下行风险包括:带量采购对洛伐他汀、七氟烷和布托啡诺的影响超出预期;研发管线进展遭遇重大挫折,未达市场预期。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">这些风险因素反映了医药行业特有的政策依赖性和研发不确定性特征。</span></p><hr style="margin: 16px 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;border-width: 0.5px 0px 0px;border-right-style: initial;border-bottom-style: initial;border-left-style: initial;border-right-color: initial;border-bottom-color: initial;border-left-color: initial;border-image: initial;border-top-style: solid;border-top-color: rgba(0, 0, 0, 0.08);color: rgb(0, 0, 0);font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-size: medium;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;" /><p style="margin-top: 0px !important;margin-right: 0px;margin-bottom: 0px;margin-left: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">截至8月20日收盘,恒瑞医药H股报收78.55港元,市值达4192亿元人民币。</span><strong style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"><span leaf="">市场现在期待的是21日下午5点的业绩说明会</span></strong><span leaf="">,管理层将对全球合作伙伴计划、授权前景、创新药审批等关键问题作出回应。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">未来6-12个月的数据读出催化剂将成为股价上涨的新引擎,特别是GLP-1和PDE3/4等重磅产品的进展。</span><span style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;"></span></p><p style="margin: 0px;padding: 0px;box-sizing: border-box;-webkit-tap-highlight-color: transparent;font-size: 14px;line-height: 24.5px;color: rgba(0, 0, 0, 0.86);text-align: justify;word-break: break-all;font-family: system-ui, -apple-system, BlinkMacSystemFont, &quot;segoe ui&quot;, Roboto, Helvetica, Arial, sans-serif;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;"><span leaf="">创新药收入占比突破55%标志着恒瑞医药已经成功转型为创新驱动型企业,授权合作模式正在成为业绩增长的新动能。</span></p><section><span leaf=""><br /></span></section><p style="display: none;"><mp-style-type data-value="3"></mp-style-type></p>

← 返回观点全库